Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.58
MRK's Cash to Debt is ranked higher than
56% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. MRK: 0.58 )
MRK' s 10-Year Cash to Debt Range
Min: 0.32   Max: 2.45
Current: 0.58

0.32
2.45
Equity to Asset 0.49
MRK's Equity to Asset is ranked higher than
57% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. MRK: 0.49 )
MRK' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.53
Current: 0.49

0.34
0.53
Interest Coverage 7.94
MRK's Interest Coverage is ranked higher than
53% of the 449 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 124.75 vs. MRK: 7.94 )
MRK' s 10-Year Interest Coverage Range
Min: 3.31   Max: 43.76
Current: 7.94

3.31
43.76
F-Score: 6
Z-Score: 3.43
M-Score: -2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.44
MRK's Operating margin (%) is ranked higher than
82% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.25 vs. MRK: 14.44 )
MRK' s 10-Year Operating margin (%) Range
Min: 5.15   Max: 37.16
Current: 14.44

5.15
37.16
Net-margin (%) 10.00
MRK's Net-margin (%) is ranked higher than
79% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. MRK: 10.00 )
MRK' s 10-Year Net-margin (%) Range
Min: 1.87   Max: 47.04
Current: 10

1.87
47.04
ROE (%) 8.85
MRK's ROE (%) is ranked higher than
77% of the 747 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.02 vs. MRK: 8.85 )
MRK' s 10-Year ROE (%) Range
Min: 1.58   Max: 45.99
Current: 8.85

1.58
45.99
ROA (%) 4.17
MRK's ROA (%) is ranked higher than
73% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.09 vs. MRK: 4.17 )
MRK' s 10-Year ROA (%) Range
Min: 0.81   Max: 17.88
Current: 4.17

0.81
17.88
ROC (Joel Greenblatt) (%) 32.08
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.47 vs. MRK: 32.08 )
MRK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 10.5   Max: 64.17
Current: 32.08

10.5
64.17
Revenue Growth (%) -0.10
MRK's Revenue Growth (%) is ranked higher than
60% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. MRK: -0.10 )
MRK' s 10-Year Revenue Growth (%) Range
Min: -24   Max: 23.1
Current: -0.1

-24
23.1
EBITDA Growth (%) 12.60
MRK's EBITDA Growth (%) is ranked higher than
79% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. MRK: 12.60 )
MRK' s 10-Year EBITDA Growth (%) Range
Min: -15.7   Max: 25.8
Current: 12.6

-15.7
25.8
EPS Growth (%) 73.80
MRK's EPS Growth (%) is ranked higher than
97% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. MRK: 73.80 )
MRK' s 10-Year EPS Growth (%) Range
Min: -42.7   Max: 73.8
Current: 73.8

-42.7
73.8
» MRK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

MRK Guru Trades in Q3 2013

Signature Select Canadian Fund 291,200 sh (New)
Jim Simons 252,300 sh (New)
Mario Gabelli 195,676 sh (+2.95%)
HOTCHKIS & WILEY 1,059,010 sh (+2.93%)
Jeremy Grantham 13,291,108 sh (+2.65%)
John Buckingham 33,169 sh (+1.75%)
James Barrow 29,641,593 sh (+1.1%)
Irving Kahn 1,228,533 sh (+1.06%)
Manning & Napier Advisors, Inc 422,047 sh (+0.56%)
RS Investment Management 1,601,873 sh (+0.38%)
Robert Bruce 261,500 sh (unchged)
Bill Nygren 1,587,000 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Leon Cooperman 203,200 sh (unchged)
Mark Hillman 17,807 sh (unchged)
Richard Snow 5,385 sh (unchged)
John Hussman 2,625 sh (unchged)
Louis Moore Bacon 1,228,000 sh (unchged)
Vanguard Health Care Fund 35,919,648 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Tom Russo 5,736 sh (unchged)
George Soros Sold Out
Caxton Associates Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Charles Brandes 2,702,972 sh (-0.02%)
Jeff Auxier 171,049 sh (-0.06%)
Murray Stahl 48,121 sh (-0.52%)
Dodge & Cox 50,137,596 sh (-1.1%)
Pioneer Investments 2,407,299 sh (-1.34%)
NWQ Managers 125,255 sh (-4.07%)
Ken Fisher 1,099,750 sh (-4.43%)
Bill Frels 113,404 sh (-16.79%)
Steven Cohen 41,275 sh (-28.3%)
Jean-Marie Eveillard 1,134,041 sh (-49.6%)
» More
Q4 2013

MRK Guru Trades in Q4 2013

Louis Moore Bacon 10,000 sh (New)
Ruane Cunniff 4,075 sh (New)
George Soros 150,000 sh (New)
Jim Simons 2,018,534 sh (+700.05%)
Irving Kahn 2,525,376 sh (+105.56%)
Bill Frels 130,654 sh (+15.21%)
Ken Fisher 1,197,965 sh (+8.93%)
John Buckingham 34,302 sh (+3.42%)
RS Investment Management 1,633,719 sh (+1.99%)
Vanguard Health Care Fund 36,561,348 sh (+1.79%)
Richard Snow 5,410 sh (+0.46%)
Louis Moore Bacon 500,000 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Mario Gabelli 195,671 sh (unchged)
George Soros 129,300 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Bill Nygren 1,587,000 sh (unchged)
Mark Hillman 17,807 sh (unchged)
John Hussman 2,625 sh (unchged)
Leon Cooperman Sold Out
Steven Cohen Sold Out
Murray Stahl 48,071 sh (-0.1%)
Jeff Auxier 170,849 sh (-0.12%)
James Barrow 29,423,811 sh (-0.73%)
NWQ Managers 123,726 sh (-1.22%)
Dodge & Cox 48,798,496 sh (-2.67%)
Manning & Napier Advisors, Inc 409,182 sh (-3.05%)
HOTCHKIS & WILEY 1,018,710 sh (-3.81%)
Pioneer Investments 2,211,185 sh (-8.15%)
Charles Brandes 2,476,201 sh (-8.39%)
Tom Russo 4,536 sh (-20.92%)
Jeremy Grantham 9,665,336 sh (-27.28%)
Jean-Marie Eveillard 14,050 sh (-98.76%)
» More
Q1 2014

MRK Guru Trades in Q1 2014

Steven Cohen 705,823 sh (New)
David Dreman 4,431 sh (New)
Joel Greenblatt 3,567 sh (New)
Paul Tudor Jones 5,035 sh (New)
Jean-Marie Eveillard 2,236,839 sh (+15820.6%)
Ruane Cunniff 4,409 sh (+8.2%)
Pioneer Investments 2,345,288 sh (+6.06%)
Signature Select Canadian Fund 299,500 sh (+2.85%)
RS Investment Management 1,668,798 sh (+2.15%)
Prem Watsa 12,000 sh (unchged)
Richard Snow 5,410 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Tom Russo 4,536 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Louis Moore Bacon Sold Out
Bill Nygren Sold Out
George Soros Sold Out
John Buckingham Sold Out
John Hussman Sold Out
HOTCHKIS & WILEY Sold Out
Murray Stahl 48,051 sh (-0.04%)
Charles Brandes 2,451,125 sh (-1.01%)
Vanguard Health Care Fund 35,616,848 sh (-2.58%)
Jeff Auxier 164,199 sh (-3.89%)
Bill Frels 114,212 sh (-12.58%)
Manning & Napier Advisors, Inc 353,494 sh (-13.61%)
Mario Gabelli 160,316 sh (-18.07%)
Dodge & Cox 39,959,196 sh (-18.11%)
James Barrow 22,739,030 sh (-22.72%)
NWQ Managers 93,255 sh (-24.63%)
Ken Fisher 725,058 sh (-39.48%)
Irving Kahn 1,128,415 sh (-55.32%)
Jeremy Grantham 2,519,078 sh (-73.94%)
Jim Simons 196,200 sh (-90.28%)
» More
Q2 2014

MRK Guru Trades in Q2 2014

George Soros 86,800 sh (New)
Joel Greenblatt 126,844 sh (+3456.04%)
Ken Fisher 6,464,243 sh (+791.55%)
Jim Simons 795,534 sh (+305.47%)
Paul Tudor Jones 13,266 sh (+163.48%)
Pioneer Investments 4,256,501 sh (+81.49%)
Manning & Napier Advisors, Inc 380,192 sh (+7.55%)
Ruane Cunniff 4,609 sh (+4.54%)
Murray Stahl 48,271 sh (+0.46%)
James Barrow 22,793,207 sh (+0.24%)
Mario Gabelli 160,316 sh (unchged)
Richard Snow 5,410 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
David Dreman Sold Out
Charles Brandes 2,434,531 sh (-0.68%)
Irving Kahn 1,120,074 sh (-0.74%)
Tom Russo 4,386 sh (-3.31%)
Vanguard Health Care Fund 33,889,948 sh (-4.85%)
Bill Frels 107,546 sh (-5.84%)
Jeff Auxier 149,734 sh (-8.81%)
NWQ Managers 84,311 sh (-9.59%)
Dodge & Cox 35,960,137 sh (-10.01%)
Jean-Marie Eveillard 1,755,082 sh (-21.54%)
RS Investment Management 861,075 sh (-48.4%)
Jeremy Grantham 340,971 sh (-86.46%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-06-30 Reduce -4.85%0.28%$54.83 - $59.62 $ 58.823%33889948
Dodge & Cox 2014-06-30 Reduce -10.01%0.23%$54.83 - $59.62 $ 58.823%35960137
Joel Greenblatt 2014-06-30 Add 3456.04%0.09%$54.83 - $59.62 $ 58.823%126844
Jean-Marie Eveillard 2014-06-30 Reduce -21.54%0.07%$54.83 - $59.62 $ 58.823%1755082
George Soros 2014-06-30 New Buy0.04%$54.83 - $59.62 $ 58.823%86800
David Dreman 2014-06-30 Sold Out 0.02%$54.83 - $59.62 $ 58.823%0
James Barrow 2014-03-31 Reduce -22.72%0.48%$49.49 - $57.47 $ 58.829%22739030
Dodge & Cox 2014-03-31 Reduce -18.11%0.45%$49.49 - $57.47 $ 58.829%39959196
Jean-Marie Eveillard 2014-03-31 Add 15820.6%0.34%$49.49 - $57.47 $ 58.829%2236839
Vanguard Health Care Fund 2014-03-31 Reduce -2.58%0.15%$49.49 - $57.47 $ 58.829%35616848
George Soros 2014-03-31 Sold Out 0.06%$49.49 - $57.47 $ 58.829%0
David Dreman 2014-03-31 New Buy0.02%$49.49 - $57.47 $ 58.829%4431
John Hussman 2014-03-31 Sold Out 0.01%$49.49 - $57.47 $ 58.829%0
Joel Greenblatt 2014-03-31 New Buy$49.49 - $57.47 $ 58.829%3567
Jean-Marie Eveillard 2013-12-31 Reduce -98.76%0.16%$45.09 - $50.18 $ 58.8223%14050
Leon Cooperman 2013-12-31 Sold Out 0.15%$45.09 - $50.18 $ 58.8223%0
Charles Brandes 2013-12-31 Reduce -8.39%0.14%$45.09 - $50.18 $ 58.8223%2476201
George Soros 2013-12-31 New Buy0.06%$45.09 - $50.18 $ 58.8223%150000
Ruane Cunniff 2013-12-31 New Buy$45.09 - $50.18 $ 58.8223%4075
Jean-Marie Eveillard 2013-09-30 Reduce -49.6%0.16%$46.55 - $48.58 $ 58.8223%1134041
George Soros 2013-09-30 Sold Out 0.13%$46.55 - $48.58 $ 58.8223%0
Joel Greenblatt 2013-09-30 Sold Out 0.05%$46.55 - $48.58 $ 58.8223%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Merck & Co Inc

Bill Nygren Comments on Merck - Apr 10, 2014

We eliminated our position in Merck (MRK) as the shares appreciated to our estimate of fair value.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Merck & Co Inc

Vanguard Health Care Fund's Top Quarterly Holdings
Over the duration of the first quarter the Vanguard Health Care Fund purchased added three new stocks to its holdings. The fund now holds on to 86 stocks valued at $35.6 billion. The following companies are Vanguard's top portfolio holdings. Read more...
Bill Nygren Comments on Merck
We eliminated our position in Merck (MRK) as the shares appreciated to our estimate of fair value. Read more...
Vanguard Health Care Fund’s Top Five
Over the duration of the fourth quarter the Vanguard Health Care Fund purchased added four new stocks to its holdings. The fund now holds on to 93 stocks valued at $32.35 billion. The following companies are Vanguard's top five portfolio holdings. Read more...
Merck and Seadrill Top GuruFocus Dividend Growers of the Week
During the past week, GuruFocus recognized two companies as dividend growers. In order to be qualified for this list, the company had to: Read more...
Diamond Hill Capital Growing - Six Sells
The updated portfolio of Diamond Hill Capital Management lists 15 stocks, 19 of them new, a total value at $9.28 billion, and a quarter-over-quarter turnover of 6%. The portfolio is currently weighted with top three sectors: financial services at 26.9%, technology at 14% and consumer defensive at 13.5%. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 31.40
MRK's P/E(ttm) is ranked higher than
76% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.60 vs. MRK: 31.40 )
MRK' s 10-Year P/E(ttm) Range
Min: 6.67   Max: 139.89
Current: 31.4

6.67
139.89
P/B 3.50
MRK's P/B is ranked higher than
62% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.42 vs. MRK: 3.50 )
MRK' s 10-Year P/B Range
Min: 1.72   Max: 7.78
Current: 3.5

1.72
7.78
P/S 4.00
MRK's P/S is ranked lower than
53% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.45 vs. MRK: 4.00 )
MRK' s 10-Year P/S Range
Min: 1.98   Max: 5.48
Current: 4

1.98
5.48
PFCF 16.90
MRK's PFCF is ranked higher than
91% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. MRK: 16.90 )
MRK' s 10-Year PFCF Range
Min: 7.8   Max: 86.81
Current: 16.9

7.8
86.81
EV-to-EBIT 28.62
MRK's EV-to-EBIT is ranked higher than
76% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.72 vs. MRK: 28.62 )
MRK' s 10-Year EV-to-EBIT Range
Min: 8.5   Max: 104
Current: 28.62

8.5
104
Shiller P/E 24.10
MRK's Shiller P/E is ranked higher than
83% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. MRK: 24.10 )
MRK' s 10-Year Shiller P/E Range
Min: 8.26   Max: 24.2
Current: 24.1

8.26
24.2
Current Ratio 1.87
MRK's Current Ratio is ranked higher than
61% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. MRK: 1.87 )
MRK' s 10-Year Current Ratio Range
Min: 1.07   Max: 3.7
Current: 1.87

1.07
3.7
Quick Ratio 1.53
MRK's Quick Ratio is ranked higher than
66% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.77 vs. MRK: 1.53 )
MRK' s 10-Year Quick Ratio Range
Min: 0.8   Max: 3.44
Current: 1.53

0.8
3.44

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.90
MRK's Dividend Yield is ranked higher than
85% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. MRK: 2.90 )
MRK' s 10-Year Dividend Yield Range
Min: 2.51   Max: 6.68
Current: 2.9

2.51
6.68
Dividend Payout 0.92
MRK's Dividend Payout is ranked higher than
67% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. MRK: 0.92 )
MRK' s 10-Year Dividend Payout Range
Min: 0.16   Max: 4.22
Current: 0.92

0.16
4.22
Dividend growth (3y) 4.40
MRK's Dividend growth (3y) is ranked higher than
80% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -0.10 vs. MRK: 4.40 )
MRK' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 14.8
Current: 4.4

0
14.8
Yield on cost (5-Year) 3.60
MRK's Yield on cost (5-Year) is ranked higher than
88% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.38 vs. MRK: 3.60 )
MRK' s 10-Year Yield on cost (5-Year) Range
Min: 3.01   Max: 8.01
Current: 3.6

3.01
8.01
Share Buyback Rate 1.30
MRK's Share Buyback Rate is ranked higher than
88% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. MRK: 1.30 )
MRK' s 10-Year Share Buyback Rate Range
Min: 1.8   Max: -13
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.80
MRK's Price/Tangible Book is ranked lower than
58% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. MRK: 9.80 )
MRK' s 10-Year Price/Tangible Book Range
Min: 3.19   Max: 3735
Current: 9.8

3.19
3735
Price/DCF (Projected) 1.60
MRK's Price/DCF (Projected) is ranked higher than
86% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.80 vs. MRK: 1.60 )
MRK' s 10-Year Price/DCF (Projected) Range
Min: 0.75   Max: 3.04
Current: 1.6

0.75
3.04
Price/Median PS Value 1.30
MRK's Price/Median PS Value is ranked higher than
54% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. MRK: 1.30 )
MRK' s 10-Year Price/Median PS Value Range
Min: 0.65   Max: 2.13
Current: 1.3

0.65
2.13
Price/Graham Number 3.60
MRK's Price/Graham Number is ranked higher than
62% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. MRK: 3.60 )
MRK' s 10-Year Price/Graham Number Range
Min: 1.08   Max: 36.98
Current: 3.6

1.08
36.98
Earnings Yield (Greenblatt) 3.50
MRK's Earnings Yield (Greenblatt) is ranked higher than
60% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. MRK: 3.50 )
MRK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 11.8
Current: 3.5

1
11.8
Forward Rate of Return (Yacktman) -2.05
MRK's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. MRK: -2.05 )
MRK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.7   Max: 17.6
Current: -2.05

-2.7
17.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0QAH.country, MRK.France, 6MK.Germany
Merck & Co Inc is a New Jersey corporation. The Company is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company's operations are mainly managed on a products basis and are comprised of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets, as well as club stores and specialty channels. The Company's competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, and generic drug and consumer health care manufacturers. The Company's activities, including research, preclinical testing, clinical trials and manufacturing and marketing its products, are subject to regulation by numerous federal, state and local governmental authorities in the United States, including the FDA, and by foreign regulatory authorities, including the European Commission.
» More Articles for MRK

Headlines

Articles On GuruFocus.com
Legendary Investor Irving Kahn's Top Five Stocks Aug 08 2014 
UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
U.S. Markets Regain Losses from Last Week Jul 14 2014 
Abner Herrman Is Increasing Position in the Pharmaceutical Sector Jul 11 2014 
U.S. Equity Markets Continue to Hit New Highs Jun 15 2014 
Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 
Will Pfizer’s Q1 2014 Earnings Beat the Street on May 5, 2014? May 05 2014 
Wrong Marketing Lesson by Big Pharma May 03 2014 
Vanguard Health Care Fund's Top Quarterly Holdings Apr 30 2014 
Bill Nygren Comments on Merck Apr 10 2014 


More From Other Websites
This stock may be hazardous to your financial health Aug 19 2014
Washington Post Off Base In Critiquing Pharma Efforts In Ebola Aug 18 2014
Biotech Leader Gilead Sciences Scores Sovaldi Win Aug 15 2014
Gilead Wins Sovaldi Dispute With Roche, U.K. Nod Aug 15 2014
MERCK & CO. INC. Financials Aug 15 2014
Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus... Aug 15 2014
Merck KGaA Q2 Earnings Slip Y/Y, 2014 Sales View Confirmed Aug 15 2014
Merck's Insomnia Drug Belsomra Approved by the FDA Aug 14 2014
[video] Pfizer and Merck Receive Key Regulatory Approvals Aug 14 2014
US STOCKS-Wall St rises after Putin comments ease Ukraine worries Aug 14 2014
US STOCKS-Wall St edges up after Putin comments, Cisco falls Aug 14 2014
US STOCKS-Wall St edges up after Putin comments, Cisco falls Aug 14 2014
Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes... Aug 14 2014
Why Pfizer (PFE) Stock Is Up Today Aug 14 2014
US STOCKS-Futures tick up ahead of jobless claims data Aug 14 2014
US STOCKS-Futures tick up ahead of jobless claims data Aug 14 2014
The F.D.A. Approves a Pill to Help People Stay Asleep Aug 13 2014
Merck Statement regarding Role of PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP... Aug 13 2014
FDA Approves BELSOMRA® (suvorexant) for the Treatment of Insomnia Aug 13 2014
FDA approves new sleeping drug from Merck Aug 13 2014
FDA approves new sleeping drug from Merck Aug 13 2014
Stocks close higher for the third time in four days on tech boost Aug 13 2014
U.S. FDA approves Merck insomnia drug Aug 13 2014
Merck Wins U.S. Approval of New Type of Sleeping Pill Aug 13 2014
Merck Reports Organic Growth in all Four Businesses in Second Quarter Aug 13 2014
Merck Serono Awards Innovation Cup and € 10,000 to Team Oncology for their Innovative Approach to... Aug 07 2014
Merck Publishes 2013 Global Corporate Responsibility Report Aug 05 2014
Merck Completes Tender Offer to Acquire Idenix Aug 05 2014
AstraZeneca steps up push into cancer immunotherapy Jul 31 2014
US STOCKS-Wall St edges lower on UPS outlook, telecom shares rally Jul 29 2014
Stocks inch up ahead of economic data Jul 29 2014
Stocks turn mixed ahead of economic data Jul 29 2014
US STOCKS-Wall St flat as telecom gains offset by earnings Jul 29 2014
Stocks turn flat at midday ahead of economic data Jul 29 2014
Merck 2Q profit more than doubles Jul 29 2014
US stocks inch higher ahead of economic reports Jul 29 2014
Merck beats forecasts, newer drugs offset impact of generics Jul 29 2014
Merck Announces Second-Quarter 2014 Financial Results Jul 29 2014
Merck Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell... Jul 29 2014
Business events scheduled for Tuesday Jul 28 2014
Merck KGaA CEO Karl-Ludwig Kley and German Federal Economics Minister Sigmar Gabriel Commission... Jul 28 2014
Merck CEO Karl-Ludwig Kley and German Federal Economics Minister Sigmar Gabriel Commission... Jul 28 2014
Merck aims to hike revenues in China to 1 bln eur by 2018 Jul 26 2014
Merck aims to hike revenues in China to 1 bln eur by 2018 Jul 26 2014
Merck aims to hike revenues in China to one billion euro by 2018 Jul 26 2014
Merck Serono Announces Collaboration with San Raffaele University & Research Hospital for Research... Jul 24 2014
Merck Announces Fourth-Quarter 2014 Dividend Jul 23 2014
Merck Strengthens Commitment to Chinese Growth Market Jul 23 2014
Merck KGaA Strengthens Commitment to Chinese Growth Market Jul 23 2014
Merck Completes Squeeze-Out of AZ Electronic Materials Jul 16 2014
Merck Serono Announces Global Grants Program to Fund Scientific Innovation Jul 16 2014
Merck Serono Appoints Luciano Rossetti as Global Head of R&D Jul 16 2014
Merck KGaA’s Biopharmaceutical Division Appoints Luciano Rossetti as Global Head of R&D Jul 14 2014
Merck KGaA pharma chief says looking at mid-size deals - paper Jul 12 2014
Strong growth at Merck’s Consumer Health Division builds on 80 years of delivery Jul 03 2014
Merck and Pharmstandard announced collaboration on production of Rebif for MS treatment in Russia Jul 01 2014
Bayer broadens healthcare line by keeping Merck's consumer brands Jul 01 2014
Bayer broadens healthcare line by keeping Merck's consumer brands Jul 01 2014
Bayer broadens healthcare line by keeping Merck's consumer brands Jul 01 2014
Merck to pay $3.85B for hepatitis C drug developer Jun 09 2014
Merck to buy Idenix Pharma for $3.85 billion Jun 09 2014
MSD to Present New Clinical Data on Sitagliptin, Investigational Omarigliptin, and Real-World Data... Jun 06 2014
Doctors use immune therapy against cervical cancer Jun 02 2014
Merck immune system-booster effective in skin, lung cancer Jun 02 2014
Boston Scientific to spend $415M on Bayer division May 15 2014
Merck KGaA ekes out profit growth on cost cuts May 15 2014
Merck makes deal worth at least $600M with Santen May 13 2014
Merck Signs Sale Agreement with Santen for Merck’s Ophthalmology Products in Japan and Key Markets... May 13 2014
FDA approves Merck blood thinner for some patients May 08 2014
Merck: New drugs pending approval or in late tests May 06 2014
Bayer wins Merck & Co's $14 billion consumer unit auction May 06 2014
Merck KGaA eyes Asia sales after completing AZ takeover May 02 2014
Merck KGaA says completes acquisition of AZ Electronic May 02 2014
Reckitt Benckiser bows out of race for Merck's consumer health arm Apr 30 2014
Reckitt Benckiser says no longer in talks with Merck Apr 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide